

Pfizer- Bapineuzumab IV Discontinuation cuts Speculation value in PFE price

https://marketpublishers.com/r/PD2E7546CB9EN.html

Date: August 2012

Pages: 1

Price: US\$ 90.00 (Single User License)

ID: PD2E7546CB9EN

Abstracts

Discontinuation of Bapinezumab IV in Alzheimer disease should knock off the speculation value embedded in the PFE share price and going forward we expect the stock price to move defensively in line with the dividend yield and share buybacks. We see downside risk if either Eliquis / Tofacitinib get trapped into regulatory hurdles. The interim results from CAPITA study exploring Prevnar 13 vaccine in adults are most likely to be inconclusive with regard to efficacy and hence may not translate into a CDC recommendation in the near future. We reiterate our market perform rating on Pfizer with a PT of \$21.



I would like to order

Product name: Pfizer- Bapineuzumab IV Discontinuation cuts Speculation value in PFE price

Product link: https://marketpublishers.com/r/PD2E7546CB9EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PD2E7546CB9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970